Propanc Biopharma, Inc. - Common Stock (PPCB)

Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock increased by

Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib

Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia

Contrasting Science with Revolution Medicines and Erasca

Accelerates Phase 1b First-in-Human Trial Timeline

Purchasing $500,000 within First 30 days Since Program Commencement

A Promising Strategy for Improving Production for Applications in Biotechnology Research

Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period

Pre-production, Engineering Run and GMP Manufacture of PRP in 2026

Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors

Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing

Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26

Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production

Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases